Latest news with #CancerTherapy
Globe and Mail
8 hours ago
- Business
- Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,' report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Oncolytic Virus Cancer Therapy Research. Learn more about our innovative pipeline today! @ Oncolytic Virus Cancer Therapy Pipeline Outlook Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report In June 2025, Replimune Inc. conducted a study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC. DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment. The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Promising Oncolytic Virus Cancer Therapy Pipeline Therapies such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others. Stay informed about the cutting-edge advancements in Oncolytic Virus Cancer Therapy treatments. Download for updates and be a part of the revolution in Oncology Care @ Oncolytic Virus Cancer Therapy Clinical Trials Assessment Oncolytic Virus Cancer Therapy Emerging Drugs Profile Olvi-Vec: Genelux Corporation Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer CAN-2409: Candel Therapeutics CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer. CG0070: CG Oncology CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer. Pelareorep: Oncolytics Biotech Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer. ParvOryx: Oryx GmbH ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer. SND005: Jiangsu Sinorda Biomedicine SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients. VCN-01: VCN Biosciences VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck. The Oncolytic Virus Cancer Therapy Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment. Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market. Learn more about Oncolytic Virus Cancer Therapy Drugs opportunities in our groundbreaking Oncolytic Virus Cancer Therapy research and development projects @ Oncolytic Virus Cancer Therapy Unmet Needs Oncolytic Virus Cancer Therapy Companies Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intranasal Intravenous Oral Oral/Intravenous Parenteral Subcutaneous Subcutaneous/Intramuscular Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as Oncolytic Virus Discover the latest advancements in Oncolytic Virus Cancer Therapy treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives Scope of the Oncolytic Virus Cancer Therapy Pipeline Report Coverage- Global Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Oncolytic Virus Cancer Therapy Pipeline Therapies- Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others. Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Oncolytic Virus Cancer Therapy Pipeline on our website @ Oncolytic Virus Cancer Therapy Emerging Drugs and Companies Table of Contents Introduction Executive Summary Oncolytic Virus Cancer Therapy: Overview Pipeline Therapeutics Therapeutic Assessment Oncolytic Virus Cancer Therapy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Olvi-Vec: Genelux Corporation Mid Stage Products (Phase II) SND005: Jiangsu Sinorda Biomedicine Early Stage Products (Phase I/II) AloCelyvir: Orgenesis Early Stage Products (Phase I) VCN-01: VCN Biosciences Preclinical and Discovery Stage Products SynOV 1.3: Beijing Syngentech Inactive Products Oncolytic Virus Cancer Therapy Key Companies Oncolytic Virus Cancer Therapy Key Products Oncolytic Virus Cancer Therapy- Unmet Needs Oncolytic Virus Cancer Therapy- Market Drivers and Barriers Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion Oncolytic Virus Cancer Therapy Analyst Views Oncolytic Virus Cancer Therapy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Associated Press
03-07-2025
- Business
- Associated Press
Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook to 2031: United States and China Lead Global Gamma Delta T Cell Therapy Clinical Trials
DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031" report has been added to offering. Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions: Adoptive gamma delta T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aß) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, gamma delta T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. gamma delta T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies. In cancer, gamma delta T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Gamma delta T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor. The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Gamma delta T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability. TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic gamma delta T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global gamma delta T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other gamma delta T cell candidates in development for various cancer indications. One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of gamma delta T cells and substantiates their role as a new therapeutic strategy. Globally, most of the research studies on gamma delta T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply gamma delta T cell treatments to these more difficult contexts. Geographically, US-based players dominate the gamma delta T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside. Moving forward, the prospects for gamma delta T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of gamma delta T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain. Company Coverage: Key Topics Covered: 1. Introduction To Gamma Delta T Cell Therapy 1.1 Emerging Role of T Cell Based Immunotherapies 1.2 Overview of Gamma Delta T Cell Therapy 1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies 2. Role of Gamma Delta T Cells in Cancer 2.1 Gamma Delta T Cells in Cancer Progression 2.2 Anti Tumor Activity of Gamma Delta T Cells 2.3 Adopted Approaches for Gamma Delta T Cell Therapy 3. Advanced Combination Strategies In Gamma Delta T Cell Therapy 4. Gamma Delta T Cell Therapy Market Overview 4.1 Current Market Scenario 4.2 Future R&D & Commercial Opportunities 4.3 Market Potential of Gamma Delta T Cell Therapy Market 4.4 Technology Platforms For Gamma Delta T Cell Therapy 4.5 Favorable Market Growth Parameters 4.6 Key Challenges To Overcome For Future Growth 5. Global Gamma Delta T Cell Therapy Clinical Trials Overview 5.1 By Phase 5.2 By Country 5.3 By Company 5.4 By Indication 5.5 By Priority Status 6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase 6.1 Research 6.2 Preclinical 6.3 Phase I 6.4 Phase I/II 6.5 Phase II 6.6 Phase II/III 7. Gamma Delta T Cell Therapy In Leukemia 7.1 Ongoing Clinical Research & Development Trends 7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia 8. Gamma Delta T Cell Therapy In Lung Cancer 8.1 Ongoing Clinical Research & Development Trends 8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer 9. Gamma Delta T Cells In Breast Cancer 9.1 Ongoing Clinical Research & Development Trends 9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer 10. Gamma Delta T Cells in Colorectal Cancer 10.1 Ongoing Clinical Research & Development Trends 10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer 11. Gamma Delta T Cells In Pancreatic Cancer 11.1 Ongoing Clinical Research & Development Trends 11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer 12. Gamma Delta T Cells In Lymphoma 12.1 Ongoing Clinical Research & Development Trends 12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma 13. Gamma Delta T Cell Therapy In Brain Tumors 13.1 Research & Development In Brain Tumors 13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors 14. Gamma Delta T Cell Therapy In Head & Neck Cancer 14.1 Research & Development In Head & Neck Cancer 14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer 15. Competitive Landscape 15.1 Acepodia 15.2 Adicet 15.3 Appia Bio 15.4 Cytomed Therapeutics 15.5 Century Therapeutics 15.6 Expression Therapeutics 15.7 Immatics 15.8 IN8bio 15.9 JY BioMed 15.10 Legend Biotech 15.11 Luminary Therapeutics 15.12 PhosphoGam 15.13 Takeda 15.14 TC Biopharm 15.15 ViGenCell For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 12:19 PM/DISC: 07/03/2025 12:19 PM
